Loading cancer entity…
Loading cancer entity…
Clinical trials
58 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07005297 | Clinical Genetics Branch Eligibility Screening Survey | not yet recruiting | — | 1,000 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07809178 | China Treatment Trial for Tumor in Sellar Region With Unruptured Intracranial Aneurysm(ChTTSRUIA) | not yet recruiting | — | 608 | Cheng senOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05041127 | Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma | active not recruiting | Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT03910465 | Children and Adults With Chordoma | recruiting | — | 300 | National Cancer Institute (NCI)NIH | 1 | Aug 27, 2026 | clinicaltrials |
| NCT05286801 | Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors | active not recruiting | Phase 1 / Phase 2 | 86 | National Cancer Institute (NCI)NIH | 3 | Jul 14, 2026 | clinicaltrials |
| NCT03874455 | Tazemetostat Expanded Access Program for Adults With Solid Tumors | no longer available | — | — | Epizyme, Inc.INDUSTRY | 0 | Jul 2, 2026 | clinicaltrials |
| NCT04416568 | Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers | active not recruiting | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06625190 | Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | University of FloridaOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT01346124 | High Dose Intensity Modulated Proton Radiation Treatment +/- Surgical Resection of Sarcomas of the Spine, Sacrum and Base of Skull | active not recruiting | N/A | 64 | Massachusetts General HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT00496119 | Proton Beam Therapy for Chordoma Patients | active not recruiting | Phase 2 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04087902 | Long-Term Longitudinal QoL in Patients Undergoing EEA | active not recruiting | — | 400 | Ohio State UniversityOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT06957327 | A Study of ERAS-601 in People With Chordoma | active not recruiting | Phase 1 / Phase 2 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05407441 | Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors | active not recruiting | Phase 1 / Phase 2 | 49 | Susan Chi, MDOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06787664 | A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma | active not recruiting | Phase 2 | 27 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05033288 | Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone | recruiting | — | 72 | Mayo ClinicOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT04091295 | BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast | available | — | — | Aveni FoundationOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT05861245 | Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base | recruiting | N/A | 20 | QuironsaludOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT02989636 | Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma | active not recruiting | Phase 1 | 21 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT02986516 | Sacral Chordoma: Surgery Versus Definitive Radiation Therapy in Primary Localized Disease(SACRO) | recruiting | N/A | 100 | Italian Sarcoma GroupNETWORK | 10 | Jan 2, 2026 | clinicaltrials |
| NCT01407198 | Nilotinib With Radiation for High Risk Chordoma | completed | Phase 1 | 23 | Massachusetts General HospitalOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT01449149 | Proton Radiation for Chordomas and Chondrosarcomas | completed | N/A | 54 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT06535997 | Descriptive Cohort of French Patients Treated With Carbonetherapy Since October 2010 Outside PHRC-ETOILE(PRIMHADRON) | completed | — | 62 | Hospices Civils de LyonOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT02601950 | A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma | completed | Phase 2 | 267 | Epizyme, Inc.INDUSTRY | 9 | Jun 22, 2025 | clinicaltrials |
| NCT04246671 | TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer | completed | Phase 1 | 37 | Bavarian NordicINDUSTRY | 1 | Mar 3, 2025 | clinicaltrials |
| NCT03647423 | QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma. | withdrawn | Phase 1 / Phase 2 | 0 | ImmunityBio, Inc.INDUSTRY | 1 | Feb 21, 2025 | clinicaltrials |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT03083678 | Afatinib in Locally Advanced and Metastatic Chordoma | completed | Phase 2 | 43 | Leiden University Medical CenterOTHER | 3 | Feb 13, 2025 | clinicaltrials |
| NCT06794645 | Pembrolizumab and Pemetrexed for Progressive Chordoma | recruiting | Phase 2 | 21 | Saint John's Cancer InstituteOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT06029218 | Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy(P1V2) | recruiting | N/A | 106 | Centre Antoine LacassagneOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT02383498 | QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma | completed | Phase 2 | 24 | NantCell, Inc.INDUSTRY | 1 | May 20, 2024 | clinicaltrials |
| NCT03623854 | Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma | completed | Phase 2 | 10 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT03242382 | Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.(PalboSarc) | unknown | Phase 2 | 40 | Grupo Espanol de Investigacion en SarcomasOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT01811394 | Ion Irradiation of Sacrococcygeal Chordoma(ISAC) | unknown | Phase 2 | 100 | Heidelberg UniversityOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT06140732 | Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma | unknown | Phase 2 | 30 | Xuanwu Hospital, BeijingOTHER | 1 | Nov 20, 2023 | clinicaltrials |
| NCT04832620 | Image Assisted Optimization of Proton Radiation Therapy in Chordomas and Chondrosarcomas(CHIPT) | recruiting | — | 40 | Leiden University Medical CenterOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT00919269 | Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma | completed | — | 150 | Children's Oncology GroupNETWORK | 7 | Oct 3, 2023 | clinicaltrials |
| NCT05707767 | A Prospective Study of Surgical Treatment Strategies for Chordoma | unknown | N/A | 100 | Xuanwu Hospital, BeijingOTHER | 1 | Jul 19, 2023 | clinicaltrials |
| NCT03595228 | BN Brachyury and Radiation in Chordoma | completed | Phase 2 | 29 | Bavarian NordicINDUSTRY | 1 | Apr 14, 2023 | clinicaltrials |
| NCT03110744 | CDK4/6 Inhibition in Locally Advanced/Metastatic Chordoma(NCT-PMO-1601) | completed | Phase 2 | 43 | University Hospital HeidelbergOTHER | 1 | Mar 27, 2023 | clinicaltrials |
| NCT03955042 | Pemetrexed for the Treatment of Chordoma | completed | Phase 1 | 15 | Saint John's Cancer InstituteOTHER | 1 | Mar 7, 2023 | clinicaltrials |
| NCT02520128 | A Study of IMRT in Primary Bone and Soft Tissue Sarcoma(IMRiS) | completed | N/A | 191 | University College, LondonOTHER | 2 | Dec 2, 2020 | clinicaltrials |
| NCT04486820 | Immunohistochemical Study of Chordomas to Improve Their Diagnosis and Prognosis Care(CHORDOMES) | completed | — | 40 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT00341627 | Genetic Aspects of Chordoma: A Collaboration With SEER Registries to Identify Chordoma Families | completed | — | 56 | National Cancer Institute (NCI)NIH | 1 | Jul 10, 2020 | clinicaltrials |
| NCT01347307 | Stereotactic Body Radiotherapy for Spine Tumors | completed | N/A | 38 | Mercy ResearchOTHER | 1 | Jun 18, 2020 | clinicaltrials |
| NCT00410670 | Chordoma Family Study | completed | — | 55 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT04042597 | Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma(CSSG-03) | unknown | Phase 2 | 60 | Peking University People's HospitalOTHER | 1 | Aug 5, 2019 | clinicaltrials |
| NCT00464620 | Trial of Dasatinib in Advanced Sarcomas | completed | Phase 2 | 366 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | Nov 23, 2018 | clinicaltrials |
| NCT00931931 | HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors | completed | Phase 1 | 18 | Timothy CripeOTHER | 1 | Mar 21, 2018 | clinicaltrials |
| NCT00003926 | Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors | terminated | Phase 1 | 13 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
Data updated 24 hours agoSource updated Sep 28, 2026source: clinicaltrials